Table 4.
Pooled analysis of the adverse events
| EUS-guided RFA for |
Procedure-related adverse events according to ASGE[9]1
|
|||
|
Mild, n (%)
|
Moderate, n (%)
|
Severe, n (%)
|
Mortality, n (%)
|
|
| Neuroendocrine neoplasms EUS-RFA sessions = 114 | 11 (9.6) | 13 (11.4) | 1 (0.9) | 1 (0.9) |
| Adenocarcinoma EUS-RFA sessions = 223 | 26 (11.6) | 3 (1.3) | 0 | 0 |
| Cystic tumors EUS-RFA sessions = 44 | 3 (6.8) | 0 | 1 (2.3) | 0 |
| Pooled data | 40 (10.5) | 16 (4.2) | 2 (0.5) | 1 (0.26) |
1
Overall, 380 EUS-RFA sessions performed for all pancreatic tumors.
ASGE: American Society of Gastrointestinal Endoscopy; EUS-RFA: Endoscopic ultrasound-radiofrequency ablation.